CLINICAL TRIAL: A STUDY TO ASSESS THE PROPHYLACTIC EFFICACY/SAFETY OF GD-ALUM/MP

临床试验：评估 GD-ALUM/MP 预防功效/安全性的研究

• 批准号: 7950788
• 负责人: DAVID BAKER
• 金额: $ 0.02万
• 依托单位: STATE UNIVERSITY NEW YORK STONY BROOK
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950788
• 关键词: Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Health; Human; Infection; Institution; Life; Research; Research Personnel; Resources; Safety; Simplexvirus; Source; United States National Institutes of Health; Vaccines; Virus; aluminum sulfate; novel vaccines; prevent; prophylactic

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to assess the efficacy and safety of this new vaccine. Herpes is a serious health problem and is the most common infections in humans. It is caused by a herpes simplex virus (HSV). Once infected, the virus stays in your body for your entire life. We are hopeful that this vaccine may prevent the spread of this infection.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这项研究的目的是评估这种新疫苗的有效性和安全性。疱疹是一种严重的健康问题，也是人类最常见的感染。它是由单纯疱疹病毒（HSV）引起的。一旦感染，病毒将终生留在您的体内。我们希望这种疫苗可以阻止这种感染的传播。